Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.

Publication

Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.

Journal Paper/Review - Oct 5, 2023

Spiera Robert F, Unizony Sebastian, Warrington Kenneth J, Sloane Jennifer, Giannelou Angeliki, Nivens Michael C, Akinlade Bolanle, Wong Wanling, Bhore Rafia, Lin Yong, Buttgereit Frank, Devauchelle-Pensec Valérie, Rubbert-Roth Andrea, Yancopoulos George D, Marrache Frederic, Patel Naimish, Dasgupta Bhaskar, SAPHYR Investigators

Citation

Spiera R, Unizony S, Warrington K, Sloane J, Giannelou A, Nivens M, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos G, Marrache F, Patel N, Dasgupta B, SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med 2023; 389:1263-1272.

Type

Journal Paper/Review (English)

Journal

N Engl J Med 2023; 389

Publication Date

Oct 5, 2023

Issn Electronic

1533-4406

Pages

1263-1272

Brief description/objective

More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in the treatment of polymyalgia rheumatica. Sarilumab, a human monoclonal antibody, binds interleukin-6 receptor α and efficiently blocks the interleukin-6 pathway.